Although most patients do not respond to these immunotherapies, therapeutic antibodies against PD‐1, PD‐L1 or CTLA4 have markedly increased progression‐free survival and overall survival in various cancers, especially when combined with chemotherapy [109, 110, 111, 112]. This evidence concerns the gene CTLA4 and cancer.